参考文献/References:
[1]Hanel W,Epperla N.Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies[J].J Hematol Oncol,2021,14(1):104.[2]Sehn LH,Salles G.Diffuse Large B-Cell Lymphoma[J].N Engl J Med,2021,384(9):842-858.[3]Teras LR,DeSantis CE,Cerhan JR,et al.2016 US lymphoid malignancy statistics by World Health Organization subtypes[J].CA Cancer J Clin,2016,66(6):443-459. [4]Lavacchi D,Landini I,Perrone G,et al.Pharmacogenetics in diffuse large B-cell lymphoma treated with R-CHOP: Still an unmet challenge[J].Pharmacol Ther,2021(24):107924. [5]Hawkes EA,Opat S,Hertzberg M.Caution in Expanding the Use of Abbreviated R-CHOP to Poor-Risk Limited-Stage DLBCL[J].J Clin Oncol,2020,38(35):4221-4222.[6]Bowzyk Al-Naeeb A,Ajithkumar T,Behan S,et al.Non-Hodgkin lymphoma[J].BMJ,2018(362):k3204.[7]Metzger ML,Mauz-K?觟rholz C.Epidemiology, outcome, targeted agents and immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin lymphoma[J].Br J Haematol,2019,185(6):1142-1157.[8]Mi M,Zhang C,Liu Z,et al.Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma: A retrospectively comparative study[J].Medicine (Baltimore),2020,99(49):e23412. [9]Batgi H,Basci S,Dal MS.Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: a single center experience[J].Turk J Med Sci,2021,51(2):685-692. [10]Batgi H,Merdin A,Dal MS,et al.The effect of gemcitabine, dexamethasone, and cisplatin chemotherapy in relapsed/refractory NHL and HL patients: A single center experience[J].J Oncol Pharm Pract,2020,26(8):1857-1863.[11]Yamasaki S,Kada A,Nagai H,et al.Phase II Trial Using Romidepsin after Gemcitabine, Dexamethasone, and Cisplatin Therapy in Elderly Transplant-Ineligible Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Study Protocol[J].Acta Med Okayama,2019,73(5):469-474. [12]Tang LQ,Chen DP,Guo L,et al.Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial[J].Lancet Oncol,2018,19(4):461-473.[13]Zhang B,Zhou F,Hong J,et al.Intravesical gemcitabine for non-muscle invasive bladder cancer[J].Cochrane Database Syst Rev,2021,6(6):CD009294.[14]Li H,Cui R,Ji M,et al.CUDC-101 enhances the chemosensitivity of gemcitabine-treated lymphoma cells[J].Leuk Res,2021(106):106575. [15]Balzarotti M,Magagnoli M,Canales MA,et al.A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma[J].Invest New Drugs,2021,39(4):1028-1035. [16]Qi F,Chen B,Wang J,et al.Upfront radiation is essential for high-risk early-stage extranodal NK/T-cell lymphoma, nasal type: comparison of two sequential treatment modalities combining radiotherapy and GDP (gemcitabine, dexamethasone, and cisplatin) in the modern era[J].Leuk Lymphoma,2019,60(11):2679-2688. [17]Namima D,Fujihara S,Iwama H,et al.The Effect of Gemcitabine on Cell Cycle Arrest and microRNA Signatures in Pancreatic Cancer Cells[J].In Vivo,2020,34(6):3195-3203.[18]Zhang XX,Wang BR,Tao WG,et al.Comparison of the efficacy and impact of GEMOX and GDP in the treatment of patients with non-Hodgkin’s lymphoma[J].J BUON,2020,25(2):1042-1049.[19]Zhang R,Lyu C,Lu W,et al.Synergistic effect of programmed death-1 inhibitor and programmed death-1 ligand-1 inhibitor combined with chemotherapeutic drugs on DLBCL cell lines in vitro and in vivo[J].Am J Cancer Res,2020,10(9):2800-2812. [20]Wang Y,Liu BY,Xu DZ,et al.Phase II trial of temozolomide plus concurrent whole-brain radiation followed by TNV regimen as adjuvant therapy for patients with newly diagnosed primary CNS lymphoma[J].Neurol India,2013,61(3):260-264.[21]Wang H,Zhu XL,Huang J,et al.Nedaplatin sensitization of cisplatin-resistant human non-small cell lung cancer cells[J].Oncol Lett,2016,11(4):2566-2572.
相似文献/References:
[1]彭玉龙,张 露,陈荣辉,等.吉西他滨与培美曲塞联合卡铂治疗晚期肺腺癌的临床观察[J].医学信息,2018,31(11):124.[doi:10.3969/j.issn.1006-1959.2018.11.039]
PENG Yu-long,ZHANG Lu,CHEN Rong-hui,et al.Clinical Observation of Gemcitabine and Pemetrexed Combined with Carboplatin in Treatment of Advanced Lung Adenocarcinoma[J].Medical Information,2018,31(08):124.[doi:10.3969/j.issn.1006-1959.2018.11.039]
[2]刘 贝,郑 慧,周 旺,等.3D-STI联合心脏综合指数评价肺癌患者GP化疗方案的隐匿性心肌毒性[J].医学信息,2019,32(08):100.[doi:10.3969/j.issn.1006-1959.2019.08.029]
LIU Bei,ZHENG Hui,ZHOU Wang,et al.Evaluation of Occult Myocardial Toxicity in GP Chemotherapy Regimen of Lung Cancer Patients by 3D-STI Combined with Cardiac Comprehensive Index[J].Medical Information,2019,32(08):100.[doi:10.3969/j.issn.1006-1959.2019.08.029]
[3]曹越越,潘跃银.吉西他滨治疗HER-2阴性转移性乳腺癌疗效的影响因素[J].医学信息,2021,34(14):70.[doi:10.3969/j.issn.1006-1959.2021.14.020]
CAO Yue-yue,PAN Yue-yin.Factors Influencing the Efficacy of Gemcitabine in the Treatment of HER-2 Negative Metastatic Breast Cancer[J].Medical Information,2021,34(08):70.[doi:10.3969/j.issn.1006-1959.2021.14.020]
[4]张书林,黄盛源,刘忠林,等.吉西他滨和多西他赛联合顺铂治疗晚期非小细胞肺鳞癌的效果比较[J].医学信息,2021,34(24):141.[doi:10.3969/j.issn.1006-1959.2021.24.036]
ZHANG Shu-lin,HUANG Sheng-yuan,LIU Zhong-lin,et al.Comparison of Gemcitabine and Docetaxel Combined with Cisplatin in the Treatment of Advanced Non-small Cell Lung Squamous Cell Carcinoma[J].Medical Information,2021,34(08):141.[doi:10.3969/j.issn.1006-1959.2021.24.036]